Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
about
Treatment for Barrett's oesophagusNovel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variantsMolecular cancer prevention: Current status and future directionsWhat is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?Oral premalignancy: the roles of early detection and chemopreventionImpaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future ResearchDisruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acidMolecular changes in the multistage pathogenesis of head and neck cancerRegulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicOngoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Effects of cigarette smoke on the human oral mucosal transcriptomep53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling.A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.PPARγ in head and neck cancer preventionDose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrencePooling prospective studies to investigate the etiology of second cancers.Association of alpha B-crystallin genotypes with oral cancer susceptibility, survival, and recurrence in Taiwan.Methylation-associated gene silencing of RARB in areca carcinogens induced mouse oral squamous cell carcinoma.Oral epithelial stem cells - implications in normal development and cancer metastasis.Second primary tumors in patients with head and neck cancer.High-throughput screening of saliva for early detection of oral cancer: a pilot study.Retinoic acid regulates cell cycle genes and accelerates normal mouse liver regeneration.Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.The effect of cigarette smoking on cancer treatment-related side effects.Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancerTobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.Correlates of continued smoking versus cessation among survivors of smoking-related cancers.Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy.No Ifs, No Butts: Compliance with Smoking Cessation in Secondary Care Guidance (NICE PH48) by Providers of Cancer Therapies (Radiotherapy and Chemotherapy) in the UK.Topical oral cavity chemoprophylaxis using isotretinoin rinse: A 15-year experience.Harm reduction and cessation efforts and interest in cessation resources among survivors of smoking-related cancersRetinoids and rexinoids in cancer prevention: from laboratory to clinic.Tumor-suppressive activity of retinoic acid receptor-beta in cancer.Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment
P2860
Q24240701-DD3E303A-E261-407C-941D-41B9566021D8Q24624194-141CDDB3-9D08-4B36-9197-3E91846E0592Q26797207-9B91E01C-D1C4-49C3-88EC-AD0267D2EBC9Q27026269-2073C1C3-AD55-43F9-BD6C-2C6A67EEE9F0Q27693327-B1E42ABF-89DD-4D85-BAAD-5CF8E7ABCB8CQ27853287-3C84F676-313C-4937-A081-EAB4596FA34DQ28085361-67CC5C18-8947-48AB-BC08-65B20D7484F4Q28469292-D0CBB80B-F55D-4EA9-BF7E-7D3451CB178DQ28728638-D26728B8-01EA-473B-AD8F-8E5E11E8BA66Q30498812-A84C4EED-1ACA-434D-B9F8-8BF4C7F0FDDEQ31001228-5D650B2F-AA41-4201-89ED-B6EF23D6D592Q33707973-3D93777B-6CEF-4EF4-98B4-91C104D29402Q33819326-DCE5DBB3-13C6-42BA-998A-C64B569FE276Q33880963-7640A572-D6B2-462B-8C56-802851281CA8Q33896090-173420B9-7488-40E3-B926-D68323BBF5C5Q33922877-212A53DB-58D2-4EEA-9474-4A456616D781Q33992357-A8A76312-8CF5-45EE-9054-924DE75587A9Q34018837-7FA9B67D-51CA-4AA0-9648-7DADB6541C5CQ34114486-47C28F12-2140-4F20-A4EF-332E64E41B2CQ34147649-BDC1EC38-615A-4584-B816-47E4CA852209Q34158978-BDFAFF12-DEB3-4AA9-87CA-496D2E2713A4Q34159301-A1CC1BB0-5ED4-47AA-BDAA-31879CFBD63CQ34539985-98E5394B-2C32-4F5A-8E65-F15D2251D666Q34611659-BF4F2CF4-D898-4FC7-86AF-B66FE75A6493Q34646050-B2BC8360-2575-44F8-A899-C789D6ED6ED1Q34790902-041A9647-A3F5-468A-B1B5-2E300640097EQ34953372-84F80B4B-82F4-4F33-B2A9-524876F2633FQ34977797-8FAEC5DE-A77D-41D8-9E65-EE1930E57D0CQ35642404-DAA69B75-CC47-43FA-8F91-A651EE4899F1Q35839993-5C43279C-0C14-4862-A403-A67A0F72CF78Q36097436-CF993947-B541-4D23-9B3C-DB8E403AA0BCQ36115675-148D9772-0185-49A9-BE02-DB472ADD7292Q36183327-4B60D346-CEC7-4557-ADCA-119DBEC022F7Q36224590-35FAFEB7-85B8-4E17-8D9A-F7F4A476E46AQ36226602-187F416C-A219-4660-97D3-3EC4918EBD31Q36230020-39458F98-99F9-49D3-9477-DFD727DF07DEQ36597905-A219A9F6-CAA1-437F-A862-60F7F1ADCDECQ36680198-44DF10D9-D928-4B80-88F4-4B4E72E18B03Q36692169-9FEBD0D6-F9ED-4FFA-B7B7-A4B46CA4CA59Q36745391-4144B627-3095-43B1-B5C5-70C4FAA4AD8A
P2860
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Randomized phase III trial of ...... head and neck cancer patients.
@en
Randomized phase III trial of ...... head and neck cancer patients.
@nl
type
label
Randomized phase III trial of ...... head and neck cancer patients.
@en
Randomized phase III trial of ...... head and neck cancer patients.
@nl
prefLabel
Randomized phase III trial of ...... head and neck cancer patients.
@en
Randomized phase III trial of ...... head and neck cancer patients.
@nl
P2093
P2860
P356
P1476
Randomized phase III trial of ...... head and neck cancer patients.
@en
P2093
Brendell Williams
Dong M Shin
Edward S Kim
Fadlo R Khuri
George Shenouda
Helmuth Goepfert
Ian Hodson
J Jack Lee
Jay S Cooper
P2860
P304
P356
10.1093/JNCI/DJJ091
P407
P577
2006-04-01T00:00:00Z